CDXC ChromaDex Corporation Stock Quote

CDXC [NASD]

Index	-	P/E	-	EPS (ttm)	-0.41	Insider Own	1.30%	Shs Outstand	66.33M	Perf Week	6.13%
Market Cap	114.75M	Forward P/E	-	EPS next Y	-0.19	Insider Trans	2.99%	Shs Float	41.06M	Perf Month	-20.28%
Income	-27.10M	PEG	-	EPS next Q	-0.08	Inst Own	32.50%	Short Float	8.38%	Perf Quarter	-37.09%
Sales	67.40M	P/S	1.70	EPS this Y	-23.80%	Inst Trans	5.54%	Short Ratio	7.23	Perf Half Y	-71.02%
Book/sh	0.52	P/B	3.33	EPS next Y	71.40%	ROA	-	Target Price	10.06	Perf Year	-77.65%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	1.51 - 10.78	Perf YTD	-53.74%
Dividend	-	P/FCF	-	EPS past 5Y	-33.50%	ROI	-	52W High	-83.95%	Beta	1.80
Dividend %	-	Quick Ratio	1.60	Sales past 5Y	25.50%	Gross Margin	61.50%	52W Low	14.57%	ATR	0.16
Employees	115	Current Ratio	2.40	Sales Q/Q	17.70%	Oper. Margin	-	RSI (14)	42.10	Volatility	12.37% 8.77%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.51	Prev Close	1.83
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 AMC	Payout	-	Avg Volume	475.80K	Price	1.73
Recom	1.60	SMA20	-6.91%	SMA50	-20.71%	SMA200	-61.71%	Volume	241,196	Change	-5.46%

Mar-08-22

Initiated

ROTH Capital

Buy

Oct-16-19

Initiated

Oppenheimer

Outperform

Feb-14-19

Initiated

B. Riley FBR

Buy

Nov-27-17

Resumed

H.C. Wainwright

Buy

$6 → $8

Sep-25-17

Initiated

Ladenburg Thalmann

Buy

Jan-03-17

Initiated

Rodman & Renshaw

Buy

May-17-22 08:27AM	How Much Of ChromaDex Corporation (NASDAQ:CDXC) Do Insiders Own? Simply Wall St. +15.09%
06:34AM	ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen® Business Wire
May-12-22 05:35PM	ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:03PM	ChromaDex Corporation Reports First Quarter 2022 Financial Results Business Wire
May-09-22 08:25AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates Zacks
May-05-22 08:35PM	Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates Zacks -7.11%
Apr-29-22 06:32AM	ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022 Business Wire -5.50%
Apr-28-22 03:02PM	ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-22-22 06:34AM	ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors Business Wire
Apr-14-22 06:32AM	ChromaDex External Research Program (CERP) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World Business Wire
Apr-06-22 06:32AM	ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio Business Wire
Mar-29-22 10:55AM	These 2 Penny Stocks Are on Track for Massive Gains, Says Oppenheimer TipRanks +9.62%
Mar-18-22 06:18AM	Trade Alert: The CEO & Director Of ChromaDex Corporation (NASDAQ:CDXC), Robert Fried, Has Just Spent US$54k Buying 1.7% More Shares Simply Wall St. +6.53%
Mar-16-22 06:31AM	ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations Business Wire +7.43%
Mar-09-22 05:15PM	ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:02PM	ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results Business Wire
Mar-08-22 08:35AM	Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Tops Revenue Estimates Zacks
Mar-02-22 06:33AM	ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinsons Disease (PD) Business Wire +8.96%
Mar-01-22 04:24AM	Investors in ChromaDex (NASDAQ:CDXC) have unfortunately lost 80% over the last year Simply Wall St.
Feb-22-22 06:34AM	ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022 Business Wire
Feb-09-22 06:34AM	ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside Business Wire +10.77%
Jan-31-22 06:32AM	ChromaDex External Research Program (CERP) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients Business Wire +8.49%
Jan-25-22 06:32AM	ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation Business Wire
Jan-22-22 07:08AM	We Think ChromaDex (NASDAQ:CDXC) Can Afford To Drive Business Growth Simply Wall St.
Jan-20-22 10:39AM	ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements Benzinga +6.88%
06:33AM	ChromaDex and Designs for Health Partner for New Product Development on Niagen® Business Wire
Dec-08-21 05:29AM	How Much Of ChromaDex Corporation (NASDAQ:CDXC) Do Insiders Own? Simply Wall St.
Nov-04-21 01:30AM	ChromaDex Corporation (CDXC) Q3 2021 Earnings Call Transcript Motley Fool
Nov-03-21 05:55PM	ChromaDex (CDXC) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:02PM	ChromaDex Corporation Reports Third Quarter 2021 Financial Results Business Wire
Oct-27-21 03:04PM	Analysts Estimate ChromaDex (CDXC) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-24-21 08:49AM	ChromaDex Corporation's (NASDAQ:CDXC) Profit Outlook Simply Wall St.
Oct-18-21 06:34AM	ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT) Business Wire -7.86%
Oct-13-21 06:33AM	ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021 Business Wire
Oct-01-21 06:33AM	ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth Business Wire
Sep-29-21 06:37AM	ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China Business Wire
Sep-20-21 06:33AM	ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP) Business Wire
Sep-15-21 04:16PM	Why ChromaDex Stock Is Sinking Today Motley Fool
08:37AM	Why Are ChromaDex Shares Trading Lower On Wednesday? Benzinga
06:30AM	ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judges Ruling in Patent Infringement Lawsuit Business Wire
Sep-09-21 06:33AM	Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now? Simply Wall St.
Aug-10-21 01:22AM	Investors in ChromaDex (NASDAQ:CDXC) have made a solid return of 118% over the past five years Simply Wall St.
Aug-03-21 10:31PM	ChromaDex Corporation (CDXC) Q2 2021 Earnings Call Transcript Motley Fool
05:25PM	ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:02PM	ChromaDex Corporation Reports Second Quarter 2021 Financial Results Business Wire
Jul-27-21 03:02PM	Analysts Estimate ChromaDex (CDXC) to Report a Decline in Earnings: What to Look Out for Zacks -9.35%
Jul-20-21 06:33AM	ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021 Business Wire
Jul-11-21 04:11AM	ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 27% Above Its Share Price Simply Wall St.
Jun-16-21 10:35AM	CHROMADEX'S HEALTHY AGING PRODUCTS GAIN NEW TRACTION WITH THREE HUGE DISTRIBUTION AGREEMENTS INCLUDING WALMART Benzinga
06:33AM	ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP) Business Wire
Jun-11-21 01:38AM	This Is The Reason Why We Think ChromaDex Corporation's (NASDAQ:CDXC) CEO Might Be Underpaid Simply Wall St.
Jun-08-21 10:40AM	ChromaDex launches Tru Niagen® in Walmart Stores; Shares Pop 7% SmarterAnalyst +14.81%
Jun-07-21 12:19PM	Why ChromaDex Stock Is Jumping Today Motley Fool
09:42AM	ChromaDex Shares Jump on Tru Niagen's Launch In Walmart Stores Benzinga
06:57AM	ChromaDex to Sell Tru Niagen Healthy-Aging Product in Walmart TheStreet.com
06:44AM	ChromaDex stock jumps after its Tru Niagen to become available at Walmart MarketWatch
06:33AM	ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States Business Wire
Jun-02-21 02:50AM	Is ChromaDex Corporation's (NASDAQ:CDXC) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
May-07-21 04:30PM	ChromaDex Corporation (CDXC) Q1 2021 Earnings Call Transcript Motley Fool -12.24%
May-06-21 06:20PM	ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:02PM	ChromaDex Corporation Reports First Quarter 2021 Financial Results Business Wire
02:45PM	Chromadex Corp. to Host Earnings Call ACCESSWIRE
May-04-21 06:33AM	ChromaDex and Ro Partner for New Product Development Business Wire
May-03-21 06:33AM	ChromaDex to Present at Benzingas Global Small Cap Conference on May 13, 2021 Business Wire
02:01AM	ChromaDex Corporation (NASDAQ:CDXC): Are Analysts Optimistic? Simply Wall St.
Apr-29-21 06:33AM	ChromaDex to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 Business Wire
Apr-28-21 06:33AM	ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen® Business Wire +6.25%
Apr-19-21 06:33AM	ChromaDex Appoints Fadi Karam as Chief Marketing Officer Business Wire
Mar-31-21 06:33AM	ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency Business Wire +6.14%
Mar-28-21 04:18AM	Is Now An Opportune Moment To Examine ChromaDex Corporation (NASDAQ:CDXC)? Simply Wall St.
Mar-24-21 06:33AM	ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference Business Wire -11.91%
Mar-22-21 08:42AM	Is the Options Market Predicting a Spike in ChromaDex (CDXC) Stock? Zacks -12.73%
Mar-18-21 06:33AM	ChromaDex to Present at the Zooming with LD Virtual Investor Conference Business Wire -6.33%
Mar-16-21 06:48PM	Why ChromaDex Trounced the Market on Tuesday Motley Fool +9.97%
Mar-11-21 12:00AM	ChromaDex Corporation (CDXC) Q4 2020 Earnings Call Transcript Motley Fool +5.21%
Mar-10-21 05:35PM	ChromaDex (CDXC) Reports Q4 Loss, Tops Revenue Estimates Zacks -6.20%
04:20PM	Recap: ChromaDex Q4 Earnings Benzinga
04:02PM	ChromaDex Corporation Reports 2020 Financial Results Business Wire
03:24PM	Why ChromaDex Stock Blasted Almost 30% Higher Today Before Falling Into the Red Motley Fool
01:30PM	Chromadex Corp. to Host Earnings Call ACCESSWIRE
06:34AM	ChromaDex Announces Retail Distribution of Tru Niagen® in Walmart Stores Across the United States Business Wire
Mar-09-21 06:32AM	ChromaDex to Present at Oppenheimer 31st Annual Healthcare Conference Business Wire +9.67%
Mar-08-21 09:00AM	ChromaDex (CDXC) Surges 12%: Is This an Indication of Further Gains? Zacks
06:31AM	ChromaDex Appoints Preventative Medicine Specialist Dr. David L. Katz to its Scientific Advisory Board Business Wire
Mar-03-21 12:30PM	ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks -8.06%
Feb-24-21 06:30AM	New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients Business Wire
Feb-22-21 06:30AM	ChromaDex Announces $25 Million Private Placement of Common Stock Business Wire +15.64%
Feb-20-21 02:17AM	Is ChromaDex's (NASDAQ:CDXC) Share Price Gain Of 110% Well Earned? Simply Wall St.
Feb-19-21 06:35AM	ChromaDex to Report Fourth Quarter 2020 Financial Results on Wednesday, March 10, 2021 Business Wire +10.51%
Feb-12-21 01:13PM	This Bioscience Company Is Trying To Defy The Aging Process Benzinga -10.43%
Feb-04-21 06:35AM	New Study Results Finds Nutritional Protocol Including Nicotinamide Riboside Reduces Liver Fat and Improves Liver Function Business Wire
Dec-22-20 12:28AM	What You Need To Know About ChromaDex Corporation's (NASDAQ:CDXC) Investor Composition Simply Wall St.
Dec-14-20 08:32AM	ChromaDex (CDXC) in Focus: Stock Moves 5.6% Higher Zacks -6.91%
Dec-02-20 03:49PM	Is ChromaDex (CDXC) A Good Stock To Buy Now? Insider Monkey
06:35AM	ChromaDex to Present at Benzingas Inaugural Small Cap Conference in December 2020 Business Wire
Nov-17-20 06:35AM	ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU) Business Wire
Nov-09-20 06:32AM	ChromaDex and Watsons Launch New TRU NIAGEN® EX Stick Packs in Hong Kong, Expanding Product Line and Advancing Global Retail Partnership Business Wire +7.13%
Nov-07-20 08:32AM	Have Insiders Been Buying ChromaDex Corporation (NASDAQ:CDXC) Shares? Simply Wall St.
08:16AM	Earnings Update: Here's Why Analysts Just Lifted Their ChromaDex Corporation (NASDAQ:CDXC) Price Target To US$8.00 Simply Wall St.
Nov-04-20 11:32PM	ChromaDex Corporation (CDXC) Q3 2020 Earnings Call Transcript Motley Fool

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fried Robert N	CEO	Mar 16	Buy	2.16	25,000	54,000	88,001	Mar 16 07:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience